ArticleJCO precision oncology2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 12 citations in OpenAlex.
- Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: a nationwide retrospective analysis.ESMO gastrointestinal oncology · 2026Article
- Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis.NPJ precision oncology · 2026Article
- Early-Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites.Cancer science · 2026Review
- Clinical and molecular characteristics of early-onset pancreatic and biliary cancers.ESMO gastrointestinal oncology · 2026Review
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- Survival outcomes and prognostic factors inFrontiers in oncology · 2026Article
- Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.JHEP reports : innovation in hepatology · 2026Article
- Impact of small area-level deprivation on survival outcomes in patients with Cholangiocarcinoma: a population-based multilevel survival analysis.Frontiers in public health · 2026Article
- Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes.JHEP reports : innovation in hepatology · 2025Article
- The increasing burden of early-onset pancreatic and biliary tract cancers: a review of risk factors.ESMO gastrointestinal oncology · 2025Review
- Early-onset gastrointestinal cancers: comprehensive review and future directions.The British journal of surgery · 2025Review
- Article
- Survival Analysis of Metastatic Young-Onset vs. Average-Onset Cholangiocarcinoma: A Population-Based Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine.The oncologist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 17 institutions in 2 countries.
Funding
Abstract
purposeIncreased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA.
methodsA multi-institutional cohort of patients with CCA diagnosed with intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma (ECC) was used for analysis. Retrospective chart review was conducted on patients who were 50 years old and younger (young; n = 124) and older than 50 years (older; n = 723).
resultsAmong 1,039 patients screened, 847 patients met eligibility (72% ICC, 28% ECC). Young patients had a larger median tumor size at resection compared with older patients (4.2
conclusionYoung patients with CCA had more advanced disease at resection, more commonly received both adjuvant and palliative therapies, and demonstrated improved survival compared with older patients. Given the low clinical trial enrollment and poor outcomes among some AYA cancer populations, data to the contrary in CCA are highly encouraging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.